E. Sutherland
Director/Board Member at KRYSTAL BIOTECH, INC.
Net worth: - $ as of 30/03/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ronald Renaud | M | 55 |
Upstream Bio, Inc.
 Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 8 years |
| Adam Tomasi | M | 54 | 7 years | |
| Daniel Janney | M | 58 | 8 years | |
| Suma M. Krishnan | F | 59 | 8 years | |
| Krish S. Krishnan | M | 59 | 8 years | |
| Robert Alexander | M | 54 | 7 years | |
| Steven James | M | 66 | 8 years | |
| Kirti Wardhaman Ganorkar | F | 57 | 7 years | |
| John Thomas | M | - | 3 years | |
| Neil Graham | M | 65 | 1 years | |
| Jonathan Silverstein | M | - |
Vanqua Bio, Inc.
 Vanqua Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Vanqua Bio, Inc. engages in the provision of technology services. The company was founded in 2019 and is headquartered in Chicago, IL. | - |
| James Sullivan | M | - |
Vanqua Bio, Inc.
Vanqua Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Vanqua Bio, Inc. engages in the provision of technology services. The company was founded in 2019 and is headquartered in Chicago, IL. | - |
| Christopher Mason | M | 66 | 3 years | |
| Bo Lin | F | - | 6 years | |
| Catherine Mazzacco | F | 59 | 1 years | |
| Julian Gangolli | M | 66 | 5 years | |
| Paul Walker | M | 49 | 7 years | |
| Harlan Radford | M | 54 | 3 years | |
| Dino Rossi | M | 69 | 7 years | |
| Robert Andreatta | M | 62 | 6 years | |
| Meg Dodge | F | - | - | |
| Eran Perry | M | - |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 3 years |
| Nate Rattner | M | - | - | |
| Marcella Ruddy | M | - |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 1 years |
| Hubert Chen | M | - | - | |
| Amy Ladd | M | 66 | 2 years | |
| Chin Lee | M | 54 | - | |
| Mary Cromwell | M | - | - | |
| Ram Kamineni | M | - | 2 years | |
| Edd Fleming | M | - |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 1 years |
| Alex Schwartz | M | - | 3 years | |
| Trevor Parry | M | - | - | |
| Kathryn Romano | F | 43 | 4 years | |
| John Karakkal | M | - | - | |
| Dolca Thomas | M | 53 | 1 years | |
| Alex Rosen | M | - |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 1 years |
| Mona Ashiya | F | - |
Vanqua Bio, Inc.
Vanqua Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Vanqua Bio, Inc. engages in the provision of technology services. The company was founded in 2019 and is headquartered in Chicago, IL. | - |
| Bernard Davitian | M | 64 |
Vanqua Bio, Inc.
Vanqua Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Vanqua Bio, Inc. engages in the provision of technology services. The company was founded in 2019 and is headquartered in Chicago, IL. | 3 years |
| Chen-Ming Yu | M | 50 |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 3 years |
| George Chen | M | - | - | |
| Rachael Borromeo | F | - | - | |
| Josh Suskin | M | - | - | |
| Stéphane Paquette | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Whitney Ijem | F | - | 2 years | |
| Jing Marantz | M | 59 | 1 years | |
| Jean-Francois Formela | M | 67 | 10 years | |
| Paul Burgess | M | 50 | 6 years | |
| Daniel Lynch | M | 65 | 9 years | |
| George Demetri | M | 67 | 2 years | |
| Owen Hughes | M | 49 | 5 years | |
| Daniella Beckman | F | 45 | 4 years | |
| Robert Meyer | M | 65 | 2 years | |
| Robert Plenge | M | 53 | 2 years | |
| Brittani Agostini | F | - | - | |
| Tiffany Hamilton | F | - | 1 years | |
| David Glynn | M | - | - | |
| Andrew Orth | M | 54 | 2 years | |
| Greg Troiano | M | - | 1 years | |
| Brendan Smith | M | 48 | - | |
| Paula Cloghessy | F | 53 | 4 years | |
| Frank DeRosa | M | - | 5 years | |
| Ann J. Barbier | M | 59 | 4 years | |
| Brian Fenton | M | 57 | 6 years | |
| Craig Paterson | M | 59 | 3 years | |
| Richard Wooster | M | 59 | 2 years | |
| Bhushan D. Hardas | M | - | 1 years | |
| John Garcia | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 67 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- E. Sutherland
- Personal Network
